PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients - PubMed (original) (raw)

Meta-Analysis

. 2008 Jun;99(6):1129-31.

doi: 10.1160/TH08-03-0130.

• PMID: 18521524
• DOI: 10.1160/TH08-03-0130

Meta-Analysis

PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients

Marilena Crescente et al. Thromb Haemost. 2008 Jun.

No abstract available

PubMed Disclaimer

Comment on

• Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.
  Reny JL, De Moerloose P, Dauzat M, Fontana P. Reny JL, et al. J Thromb Haemost. 2008 Mar;6(3):444-50. doi: 10.1111/j.1538-7836.2008.02897.x. Epub 2008 Jan 10. J Thromb Haemost. 2008. PMID: 18194417 Review.
• Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
  Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Krasopoulos G, et al. BMJ. 2008 Jan 26;336(7637):195-8. doi: 10.1136/bmj.39430.529549.BE. Epub 2008 Jan 17. BMJ. 2008. PMID: 18202034 Free PMC article. Review.

Similar articles

• Aspirin resistance: focus on clinical endpoints.
  Pusch G, Feher G, Kotai K, Tibold A, Gasztonyi B, Feher A, Papp E, Lupkovics G, Szapary L. Pusch G, et al. J Cardiovasc Pharmacol. 2008 Dec;52(6):475-84. doi: 10.1097/FJC.0b013e31818eee5f. J Cardiovasc Pharmacol. 2008. PMID: 19034037 Review.
• Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry.
  Motovska Z, Sujanova Z, Wimmerova S, Ardo J, Skrakova M, Widimsky P. Motovska Z, et al. Transl Res. 2007 Oct;150(4):246-52. doi: 10.1016/j.trsl.2007.02.004. Epub 2007 May 25. Transl Res. 2007. PMID: 17900512 Clinical Trial.
• Aspirin resistance in patients with chronic renal failure.
  Tanrikulu AM, Ozben B, Koc M, Papila-Topal N, Ozben T, Caymaz O. Tanrikulu AM, et al. J Nephrol. 2011 Sep-Oct;24(5):636-46. doi: 10.5301/JN.2011.6259. J Nephrol. 2011. PMID: 21279952
• Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function.
  Bevilacqua S, Alkodami AA, Volpi E, Cerillo AG, Berti S, Glauber M, Gianetti J. Bevilacqua S, et al. Ann Thorac Surg. 2009 Feb;87(2):496-502. doi: 10.1016/j.athoracsur.2008.05.038. Ann Thorac Surg. 2009. PMID: 19161767
• A critical appraisal of the phenomenon of aspirin resistance.
  Svenstrup Poulsen T, Kristensen SR, Atar D, Mickley H. Svenstrup Poulsen T, et al. Cardiology. 2005;104(2):83-91. doi: 10.1159/000086690. Epub 2005 Jul 5. Cardiology. 2005. PMID: 16020925 Review.

Cited by

• Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes.
  Addad F, Chakroun T, Elalamy I, Abderazek F, Chouchene S, Dridi Z, Gerotziafas GT, Hatmi M, Hassine M, Gamra H. Addad F, et al. Int J Hematol. 2010 Sep;92(2):296-301. doi: 10.1007/s12185-010-0652-3. Epub 2010 Aug 20. Int J Hematol. 2010. PMID: 20725815 Clinical Trial.
• The efficacy of aspirin to inhibit platelet aggregation in patients hospitalised with a severe infection: a multicentre, open-label, randomised controlled trial.
  van Zijverden LM, Schutte MH, Madsen MC, Bonten TN, Smulders YM, Wiepjes CM, van Diemen JJK, Thijs A. van Zijverden LM, et al. Clin Exp Med. 2023 Nov;23(7):3501-3508. doi: 10.1007/s10238-023-01101-5. Epub 2023 Jun 9. Clin Exp Med. 2023. PMID: 37294478 Free PMC article. Clinical Trial.
• Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction.
  Gianetti J, Parri MS, Della Pina F, Marchi F, Koni E, De Caterina A, Maffei S, Berti S. Gianetti J, et al. ScientificWorldJournal. 2013 Dec 19;2013:313492. doi: 10.1155/2013/313492. eCollection 2013. ScientificWorldJournal. 2013. PMID: 24453831 Free PMC article. Clinical Trial.
• Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents.
  Arai T, Kawamura A, Matsubara Y, Yokoyama K, Ikeda Y, Fukuda K, Murata M. Arai T, et al. Heart Vessels. 2012 Sep;27(5):480-5. doi: 10.1007/s00380-011-0180-y. Epub 2011 Aug 12. Heart Vessels. 2012. PMID: 21837496
• Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease.
  Gurbel PA, Tantry US. Gurbel PA, et al. Curr Treat Options Cardiovasc Med. 2009 Feb;11(1):22-32. doi: 10.1007/s11936-009-0003-y. Curr Treat Options Cardiovasc Med. 2009. PMID: 19141258

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Georg Thieme Verlag Stuttgart, New York
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information